InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite, as the genomics specialist concentrates investment around its DNAimpact precision health platform. Arcadia Capital, which served as InformedDNA’s exclusive financial adviser, announced the transaction on August 18, 2026, with financial terms not disclosed.
The transaction is more revealing when viewed alongside InformedDNA’s portfolio activity earlier this year. The company, which is backed by Truehelm and QHP Capital, also divested its Payment Integrity business in May 2026. The latest disposal therefore represents a second meaningful separation of a payer-focused service line as InformedDNA concentrates its strategy around applying genetic information more directly within precision health programs.
That distinction is important. InformedDNA is not retreating from genetic testing. Instead, it appears to be narrowing the part of the genetics value chain it wants to own. Genetic Testing Utilization Management is principally concerned with helping health plans determine whether particular genetic tests are clinically appropriate and whether spending is justified. DNAimpact, by contrast, is positioned around identifying genetic risk, supporting testing and counseling, and connecting genomic information with personalized healthcare pathways.
For Zyter, the transaction moves in the opposite strategic direction. The company is adding a specialized genetic testing capability to an existing population health and utilization management platform that already serves health plans. That creates the possibility of taking InformedDNA’s genetics-specific clinical review expertise and embedding it within a much larger payer workflow environment.
Why is InformedDNA separating genetic testing utilization management from its DNAimpact growth strategy?
The Genetic Testing Utilization Management business sits at an increasingly complex intersection of medicine and payer economics.
Arcadia Capital said the operation works with health plans and combines genetics-trained specialists with evidence-based review to determine whether genetic tests are clinically appropriate. The objective is to help members receive appropriate testing while reducing expenditure on tests that do not meet the relevant clinical criteria.
That role has become harder as the genetic testing landscape expands. A payer evaluating a relatively straightforward laboratory service can often rely on established policies and coding structures. Genetic tests can demand considerably more specialist interpretation because clinical appropriateness may depend on disease characteristics, family history, previously performed tests, the precise gene or panel involved and whether the result is likely to alter management.
InformedDNA built expertise around that problem, but the company’s current strategic emphasis increasingly points elsewhere.
DNAimpact is described by InformedDNA as a precision health platform spanning areas including oncology, neurology, metabolic health, pharmacogenomics, cardiology, hereditary cancer, reproductive health and women’s health. The company positions the platform as connecting genomic science with prevention, diagnosis and more individualized treatment approaches for health plans and employers.
The strategic difference is substantial. Utilization management primarily governs whether testing should occur. DNAimpact is intended to participate more broadly in identifying people who may benefit from genomic information and supporting the journey through education, testing, specialist interpretation and subsequent health decisions.
Divesting GTUM can therefore be read as portfolio concentration rather than abandonment of a core competency. InformedDNA is choosing which part of the genomics ecosystem it believes offers the stronger long-term strategic fit.
What does Zyter gain from acquiring a genetics-specialist utilization management operation?
Zyter gains something that could be difficult to reproduce rapidly through software development alone: specialized clinical genetics knowledge embedded in payer utilization management.
The company already operates TruCare, a population health platform covering care management, case management and utilization management. Zyter has said its technology supports more than 44 million covered lives across more than 45 health plans, providing a potentially broad installed base through which additional payer capabilities can be introduced. Those figures are company-reported and do not indicate how many clients will ultimately use the acquired genetic testing service.
The fit nevertheless appears relatively direct.
General utilization management technology can automate workflows, apply rules, coordinate authorization processes and route cases for review. Genetics creates an additional layer because rapidly changing testing options can require specialist interpretation of clinical indications and medical evidence.
Bringing InformedDNA’s GTUM capability into that environment could allow Zyter to offer payers a more specialized review layer without forcing health plans to maintain the entire genetic testing expertise internally.
The commercial opportunity, however, cannot be quantified from the transaction announcement. Neither revenue from the acquired operation nor customer numbers, margins or purchase consideration were disclosed. The announcement also does not provide enough detail to determine precisely which personnel, intellectual property, client agreements or technology components transferred.
Those omissions matter because strategic fit and financial significance are not the same thing. The acquisition may enhance Zyter’s clinical capabilities without immediately becoming a material revenue contributor.
Why does the May Payment Integrity divestiture make the Zyter transaction more significant?
The clearest indication that InformedDNA is undergoing a deliberate portfolio redesign is the timing of the two divestitures.
Its Payment Integrity business was acquired by Machinify earlier in 2026. Machinify subsequently described the acquired capability as genetic testing payment integrity expertise that could be incorporated into its broader payment intelligence platform, including review of genetic testing claims in conjunction with payer medical policies.
Payment integrity and utilization management address different stages of healthcare spending, but both serve payer cost-control functions.
Utilization management can influence whether a service should proceed or qualify for coverage. Payment integrity focuses more heavily on whether claims have been processed and paid correctly. InformedDNA has now separated both activities while retaining its broader precision health ambitions.
That pattern gives the latest transaction greater meaning than a stand-alone sale.
InformedDNA Chief Executive Officer Surya Singh indicated in the transaction announcement that the company intends to continue working with Arcadia Capital following the two divestitures, while Truehelm partner and InformedDNA board member Conor Green framed the strategy around sharpening the company’s focus on genetic testing for precision health.
The messaging suggests that management and its investors see DNAimpact not simply as another offering inside InformedDNA but as the platform around which the company should increasingly organize its resources.
How different is DNAimpact from the payer cost-control businesses InformedDNA has sold?
DNAimpact pushes InformedDNA further toward population health and participant engagement, which brings a different commercial model and a different set of execution challenges.
The platform covers multiple health areas and is intended to connect individuals with genomic education, genetic testing and expert support. InformedDNA also describes pharmacogenomics as part of DNAimpact, giving the platform potential relevance to how genetic differences may influence medication response.
That creates a broader ambition than reviewing whether a test is appropriate.
For an employer or health plan buying a precision health program, success can depend on identifying the right population, persuading eligible members to participate, coordinating testing, ensuring access to genetics professionals, supporting providers and ultimately demonstrating that the program produces enough clinical or economic value to justify continued spending.
Those hurdles should not be underestimated.
A platform can technically identify genetic risk without necessarily changing downstream healthcare utilization or outcomes. Similarly, increasing access to testing does not by itself establish economic value for a payer. InformedDNA’s longer-term commercial case will therefore depend increasingly on evidence generated through actual deployments, including engagement, testing completion, resulting clinical actions and purchaser retention.
The benefit of the portfolio simplification is that management can devote more attention and capital to solving precisely those problems.
Could specialized genetic testing review become more valuable as payer complexity increases?
The underlying rationale for the acquired business is strengthened by the widening use of genomic information across medicine.
Genetic testing is no longer confined to a narrow group of rare disease applications. Oncology, inherited cardiovascular disease, reproductive health, neurologic conditions and pharmacogenomics are among areas in which genomic information can enter clinical decision-making.
That expansion can create a paradox for payers. Wider availability of testing can improve access to clinically relevant information, but it also increases the number of tests, panels and testing scenarios that must be evaluated.
Utilization management is therefore not merely an exercise in restricting testing. At its strongest, the model attempts to distinguish clinically justified testing from redundant, poorly targeted or insufficiently supported use.
Specialist expertise becomes especially relevant when the clinical question cannot be reduced to a simple authorization rule.
This is where Zyter’s acquisition rationale becomes more persuasive. An enterprise payer platform can handle workflow at scale, while an inherited body of genetics expertise can potentially improve the quality of the decisions flowing through that workflow.
The challenge will be preserving that expertise during integration. The more automated payer operations become, the more important it is that complex clinical cases are not reduced to administrative rules that overlook nuances in evidence, phenotype or testing strategy.
What remains unknown about the InformedDNA and Zyter transaction?
The largest unanswered questions are commercial.
The parties did not disclose the purchase price, the size or profitability of the GTUM business, its number of health-plan customers or the volume of genetic testing reviews it performs. There is consequently no reliable basis to attach a valuation to the divested unit or estimate the immediate revenue benefit for Zyter.
It is also unclear whether Zyter intends to market the operation as a distinct genetics service, integrate it completely into TruCare, or eventually combine specialist review with newer automation and artificial intelligence capabilities.
The distinction could influence how scalable the asset becomes.
A predominantly services-based genetics review operation may depend heavily on specialist staffing as volumes grow. A more technology-enabled model could potentially increase reviewer productivity, but clinical quality and auditability would remain central because inappropriate utilization decisions can affect both patient access and payer expenditure.
For InformedDNA, the key unknown is what happens with the capital and organizational capacity released by two business disposals. The company has emphasized continued investment in DNAimpact, but the transaction announcement does not disclose how much additional funding will be directed toward product development, sales expansion or new clinical programs.
What will show whether InformedDNA’s narrowed precision health strategy is working?
The significance of the Zyter transaction will ultimately be judged less by the divestiture itself than by what InformedDNA does after it.
Two business-unit sales have produced a clearer strategic profile. InformedDNA is progressively separating payer spending-control activities while keeping a platform designed to broaden the practical use of genomics in health management.
Clarity, however, creates a more demanding performance test.
DNAimpact now carries more of the strategic burden. Growth in covered populations, health-plan and employer adoption, participant engagement, expansion across disease programs and evidence that genomic interventions translate into measurable clinical or economic outcomes will become increasingly important indicators of whether the portfolio redesign is creating value.
Zyter faces a different test. Its acquisition needs to show that genetics-specific clinical expertise can be integrated into a large utilization-management platform without becoming diluted into generic payer workflow automation.
The transaction therefore leaves the two companies on increasingly distinct sides of the same genomic healthcare market. InformedDNA is concentrating on putting genetic information to work within precision health. Zyter is strengthening the infrastructure used by payers to determine when genetic testing is clinically appropriate and economically defensible.
If both strategies work, the unusual part of this deal may not be that InformedDNA sold a genetics business. It may be that the rapidly expanding genomics market has become mature enough for companies to specialize more aggressively in different parts of the testing, care-management and payment chain.